City of Hope Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, City of Hope Medical Center sits in the top decile of US sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count).
City of Hope Medical Center: 582 sponsored US clinical trials, 167 recruiting.
City of Hope Medical Center sponsors 582 registered US clinical trials on ClinicalTrials.gov, 167 of them currently recruiting, and 217 completed. 9 of these trials are in Phase 3-4 (later-stage) and 382 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 22 trials.
Top-decile sponsor footprint
City of Hope Medical Center ranks in the top decile of sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
217 of 245 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
582 total, page 4 of 12
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT04484012
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
NCT04510051
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04508790
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
NCT03975231
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT04329494
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
NCT03969446
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT04305834
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT06342440
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
NCT04003649
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
NCT03728335
Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes
NCT03746769
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
NCT03710421
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
NCT03523975
Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations
NCT04160429
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
NCT03354728
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
NCT03422731
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge
NCT06625619
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study
NCT05786456
Epigenetic Signature for CRC Early Detection
NCT07224854
Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy
NCT06169267
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
NCT06112847
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT06049576
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca
NCT06008158
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
NCT05718869
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
NCT05672316
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
NCT05627635
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
NCT05707273
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
NCT05428176
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
NCT05364762
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05441514
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
NCT05470699
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
NCT05222984
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
NCT05139004
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
NCT05384756
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
NCT05173961
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT04939272
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
NCT05023993
Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors
NCT05138991
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT05340673
An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
NCT04590872
Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer
NCT05868486
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
NCT05139043
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
NCT05166616
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
NCT05014646
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
NCT04929392
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT05162976
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
NCT04905082
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
NCT05122546
Perioperative Telemonitoring to Optimize Cancer Care and Outcomes
NCT04986566
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 240 |
| Phase 2 | 142 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the City of Hope Medical Center pipeline
167 recruiting of 582 indexed (29% open); 217 completed (37%).
Phase mix: 9 late (III/IV) vs 382 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (22 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
City of Hope Medical Center: open-pipeline peers nationwide
Peers matched on 582 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 582 trials (± recruiting share)
- Bayer · 591 trials · 4% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Methodist Health System · 29% recruiting · 125 trials
- 89bio · 29% recruiting · 7 trials
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
Related
What to do with this City of Hope Medical Center page
582 registered trials is a research-attention snapshot, not an endorsement of City of Hope Medical Center or any single study.
- 167 of City of Hope Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition City of Hope Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. City of Hope Medical Center pipeline card: 582 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.